How do I manage cervicitis during chemo at age 35?

Question

Hello doctor,

I am a 35-year-old female undergoing chemotherapy (ABVD regimen) for stage II Hodgkin’s lymphoma. Over the past two weeks, I have developed persistent lower pelvic discomfort, foul-smelling vaginal discharge, and occasional spotting outside my cycle. A pelvic exam revealed an inflamed cervix, and the cervical swab confirmed cervicitis.

I am concerned because my recent CBC shows neutropenia with an absolute neutrophil count of 850 cells/µL, and my CRP is elevated at 24 mg/L. My vaginal pH was noted to be 5.8, and my Pap smear showed inflammatory changes but no malignancy.

Given my immunocompromised state due to chemotherapy, I am worried about the risk of ascending infections. My ESR is also elevated at 62 mm/hr. I am on Filgrastim to boost my counts, but the cervicitis symptoms have not improved with local antibiotic gel.

Could this be a treatment-related opportunistic infection, and should the cervicitis be managed more aggressively, considering my low immunity and ongoing lymphoma treatment?

Please advise.

Answer 1

Hello,

Welcome to icliniq.com

I read your query and understand your concern.

Given your immunocompromised state due to ongoing ABVD (Adriamycin, Bleomycin, Vinblastine, and Dacarbazine) chemotherapy for stage II Hodgkin’s lymphoma, the persistence of cervicitis symptoms like lower pelvic discomfort, foul-smelling discharge, and spotting along with laboratory findings such as neutropenia (ANC absolute neutrophil count 850/µL), elevated CRP C-reactive protein (24 mg/L), ESR erythrocyte sedimentation rate ESR (62 mm/hr), and a vaginal pH of 5.8, need more aggressive management.

The presence of cervical inflammation despite local antibiotic gel strongly suggests that this is an opportunistic or polymicrobial infection like Chlamydia trachomatis, Mycoplasma genitalium, Gardnerella vaginalis, anaerobes, or even fungal infection.

In immunocompromised patients, local treatments are often insufficient, and there is an elevated risk of ascending infection, endometritis, or systemic involvement, especially with compromised neutrophil-mediated immunity. Given these concerns, systemic antibiotic therapy should be initiated commonly with a combination of Doxycycline and Metronidazole, or Azithromycin with Metronidazole, if tolerated better, with Ceftriaxone added if gonorrhea is a concern.

Consult your specialist doctor, discuss with him or her, and take the medicines with their consent.

Additionally, it is essential to:

Repeat cervical swabs, polymerase chain reaction-based sexually transmitted infection panels to identify atypical or resistant organisms.
Pelvic ultrasound is also necessary to rule out deeper pelvic infections or abscesses.
Continue the use of Filgrastim to support neutrophil recovery,
Strict hygiene measures, possibly with assisted care, should be maintained to reduce further risk.

Timely and comprehensive treatment is critical to prevent progression or systemic complications in the setting of chemotherapy-induced immunosuppression.

I hope this helps.

Thank you.